SCARB2;CD36L2;LIMP2;LIMPII

Lysosome membrane protein 2 (85 kDa lysosomal membrane sialoglycoprotein) (LGP85) (CD36 antigen-like 2) (Lysosome membrane protein II) (LIMP II) (Scavenger receptor class B member 2) (CD antigen CD36)

Homo sapiens (Human)

54290

478

Pending Verification

Lysosome membrane protein 2 (85 kDa lysosomal membrane sialoglycoprotein) (LGP85) (CD36 antigen-like 2) (Lysosome membrane protein II) (LIMP II) (Scavenger receptor class B member 2) (CD antigen CD36)

Epilepsy, progressive myoclonic 4, with or without renal failure (EPM4) [MIM:254900]: An autosomal recessive progressive myoclonic epilepsy associated with renal failure in some cases. Cognitive function is preserved. Myoclonus is a brief, involuntary twitching of a muscle or a group of muscles. {ECO:0000269|PubMed:18308289, ECO:0000269|PubMed:18424452, ECO:0000269|PubMed:19454373, ECO:0000269|PubMed:21670406}. Note=The disease is caused by mutations affecting the gene represented in this entry.; Note=Genetic variants in SCARB2 can act as modifier of the phenotypic expression and severity of Gaucher disease. {ECO:0000269|PubMed:21796727}.

MUTAGEN 475 475 L->A,G,D,V: Prevents the targeting of the protein to lysosomes. {ECO:0000269|PubMed:7509809}.; MUTAGEN 475 475 L->I: Some loss in the efficiency of targeting of the protein to lysosomes. {ECO:0000269|PubMed:7509809}.; MUTAGEN 476 476 I->A,V: Does not prevent the targeting of the protein to lysosomes completely. {ECO:0000269|PubMed:7509809}.; MUTAGEN 476 476 I->D,E,G: Prevents the targeting of the protein to lysosomes. {ECO:0000269|PubMed:7509809}.; MUTAGEN 476 476 I->L: Normal targeting of the protein to lysosomes. {ECO:0000269|PubMed:7509809}.; MUTAGEN 477 477 R->A,E,G,K,Q: Normal targeting of the protein to lysosomes. {ECO:0000269|PubMed:7509809}.; MUTAGEN 478 478 T->G,I,S,V: Normal targeting of the protein to lysosomes. {ECO:0000269|PubMed:7509809}.

MGRCCFYTAGTLSLLLLVTSVTLLVARVFQKAVDQSIEKKIVLRNGTEAFDSWEKPPLPVYTQFYFFNVTNPEEILRGETPRVEEVGPYTYRELRNKANIQFGDNGTTISAVSNKAYVFERDQSVGDPKIDLIRTLNIPVLTVIEWSQVHFLREIIEAMLKAYQQKLFVTHTVDELLWGYKDEILSLIHVFRPDISPYFGLFYEKNGTNDGDYVFLTGEDSYLNFTKIVEWNGKTSLDWWITDKCNMINGTDGDSFHPLITKDEVLYVFPSDFCRSVYITFSDYESVQGLPAFRYKVPAEILANTSDNAGFCIPEGNCLGSGVLNVSICKNGAPIIMSFPHFYQADERFVSAIEGMHPNQEDHETFVDINPLTGIILKAAKRFQINIYVKKLDDFVETGDIRTMVFPVMYLNESVHIDKETASRLKSMINTTLIITNIPYIIMALGVFFGLVFTWLACKGQGSMDEGTADERAPLIRT

Acts as a lysosomal receptor for glucosylceramidase (GBA) targeting. {ECO:0000269|PubMed:18022370}.; (Microbial infection) Acts as a receptor for enterovirus 71. {ECO:0000269|PubMed:19543282}.

Alternative sequence (1); Beta strand (21); Chain (1); Disulfide bond (2); Glycosylation (10); Helix (17); Mass spectrometry (1); Mutagenesis (7); Natural variant (2); Region (1); Sequence conflict (1); Topological domain (3); Transmembrane (2); Turn (7)

Lysosome membrane protein 2 (85 kDa lysosomal membrane sialoglycoprotein) (LGP85) (CD36 antigen-like 2) (Lysosome membrane protein II) (LIMP II) (Scavenger receptor class B member 2) (CD antigen CD36)

Recombinant

HEK293

Lyophilized

7.4-7.5

Sterile-filtered colorless solution

1mg/ml

Standard

PBS

SDS-PAGE

> 98%

RP-HPLC

-20°C

This bioreagent is stable at 4°C (short-term) and -70°C(long-term). After reconstitution, sample may be stored at 4°C for 2-7 days and below -18°C for future use.

Reconstitute in sterile distilled H2O to no less than 100ug/ml; dilute reconstituted stock further in other aqueous solutions if needed. Please review COA for lot-specific instructions. Final measurements should be determined by the end-user for optimal performance.